english.prescrire.org > Topics > Advancing healthcare policy > Advancing healthcare policy in Europe: a chronological recap of actions > 2023 Recap > Impending changes to European pharmaceutical regulations: part II (January 2023)

Advancing healthcare policy

Advancing healthcare policy in Europe: a chronological recap of actions

A recap of actions in 2023
Impending changes to European pharmaceutical regulations: part II (January 2023)

In order to prepare its new "Pharmaceutical Strategy for Europe", the European Commission organised several public consultations in advance. The present article reproduces extensive excerpts from a report published by the European Parliamentary Research Service, produced in connection with these consultations, which calls for the creation of a "European Medicines Infrastructure".

  • The report published by the European Parliamentary Research Service analyses the strengths and weaknesses of the current pharmaceutical research and development (R&D) model in Europe. It then proposes a new approach to pharmaceutical policy, including the creation of a Europe-­wide public R&D infrastructure.
     
  • Future Prescrire articles will address the announced revisions of the EU's general pharmaceutical legislation and legislation on rare diseases and paediatric drugs.

©Prescrire 1 January 2023

Source: "Impending changes to European pharmaceutical regulations: part II" Prescrire International 2023; 32 (244): 23-25. Free.

Enjoy full access to Prescrire International, and support independent information

Share
Share on Facebook Share on Twitter